Payment overview · 2025
General Payments
$972.06
41 reported records · 12 companies
Healthcare provider profile · identity verified
Thomas Wesley Wells, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · WATKINSVILLE, GA · NPI 1356301436
Verified facts
What the public records show
CMS Open Payments records show Thomas Wesley Wells, M.D. received $972.06 in general payments during 2025 across 41 reported records.
Amgen Inc. accounted for 34.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $330.66 | 34.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $190.11 | 19.6% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.62 | 14.6% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $63.53 | 6.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.69 | 5.9% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $49.15 | 5.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.63 | 3.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.54 | 2.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.36 | 2.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.55 | 2.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.32 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.90 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $972.06 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $290.03 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $141.62 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $119.35 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.76 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $63.53 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.83 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.69 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $49.15 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $40.63 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $40.63 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 85 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 110 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 15 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
110 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 501 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 125 |
| Losartan Potassium | Losartan Potassium | 302 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 107 |
| Lisinopril | Lisinopril | 247 | 75 |
| Omeprazole | Omeprazole | 247 | 79 |
| Gabapentin | Gabapentin | 242 | 69 |
| Metformin Hcl Er | Metformin Hcl | 192 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 68 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 63 |
| Famotidine | Famotidine | 155 | 52 |
| Trazodone Hcl | Trazodone Hcl | 154 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 51 |
| Alprazolam | Alprazolam | 149 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 144 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 43 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 139 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 39 |
| Potassium Chloride | Potassium Chloride | 131 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 33 |
| Meloxicam | Meloxicam | 120 | 39 |
| Metformin Hcl | Metformin Hcl | 119 | 40 |
| Simvastatin | Simvastatin | 112 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 35 |
| Mounjaro | Tirzepatide | 110 | 24 |
| Montelukast Sodium | Montelukast Sodium | 105 | 35 |
| Celecoxib | Celecoxib | 104 | 23 |
| Clonazepam | Clonazepam | 103 | 20 |
| Furosemide | Furosemide | 100 | 34 |
| Jardiance | Empagliflozin | 94 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 33 |
| Farxiga | Dapagliflozin Propanediol | 85 | 22 |
| Glimepiride | Glimepiride | 84 | 25 |
| Bupropion Xl | Bupropion Hcl | 81 | 18 |
| Chlorthalidone | Chlorthalidone | 79 | 24 |
| Eliquis | Apixaban | 76 | 21 |
| Sertraline Hcl | Sertraline Hcl | 73 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 13 |
| Allopurinol | Allopurinol | 69 | 22 |
| Buspirone Hcl | Buspirone Hcl | 69 | 21 |
| Cefdinir | Cefdinir | 67 | 54 |
| Prednisone | Prednisone | 67 | 28 |
| Pregabalin | Pregabalin | 67 | 21 |
| Donepezil Hcl | Donepezil Hcl | 66 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 23 |
| Ozempic | Semaglutide | 64 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 21 |
| Tramadol Hcl | Tramadol Hcl | 62 | 23 |
| Atenolol | Atenolol | 59 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 14 |
| Carvedilol | Carvedilol | 53 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 14 |
| Memantine Hcl | Memantine Hcl | 52 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 35 |
| Mirtazapine | Mirtazapine | 50 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 16 |
| Ramipril | Ramipril | 45 | 16 |
| Alendronate Sodium | Alendronate Sodium | 44 | 17 |
| Baclofen | Baclofen | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 16 |
| Trulicity | Dulaglutide | 41 | 11 |
| Carisoprodol | Carisoprodol | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 14 |
| Methylprednisolone | Methylprednisolone | 38 | 36 |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 23 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Mupirocin | Mupirocin | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 11 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 13 |
| Azelastine Hcl | Azelastine Hcl | 28 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 14 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 14 |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $972.06 · 41 records | Amgen Inc. | AIRSUPRA, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, MOUNJARO, Ozempic, PROLIA, REPATHA, Rybelsus, SHINGRIX, TZIELD, The Cologuard Plus Collection Kit, VOQUEZNA, VYEPTI, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error